Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA granted full approval of Synribo (omacetaxine mepesuccinate) for injection following the drug’s accelerated approval in October 2012, which was conditioned on the provision of additional clinical trial data to fulfill post-marketing requirements.